Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation-Reference-Cited by-同舟云学术

Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation

Published:2020-04-21 Issue: Volume: Page:
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Langenhorst Jurgen B.¹²³,Dorlo Thomas P.C.⁴^ORCID,Kesteren Charlotte¹,Maarseveen Erik M.⁵,Nierkens Stefan¹²,Witte Moniek A.⁶,Boelens Jaap Jan¹⁷,Huitema Alwin D.R.⁴⁵

Affiliation:

1. Pediatric Blood and Marrow Transplant Program Princess Maxima Center for Pediatric Oncology Utrecht The Netherlands

2. Laboratory of Translational Immunology University Medical Centre Utrecht (UMCU) Utrecht University Utrecht The Netherlands

3. Model-informed drug development consultant Pharmetheus AB Uppsala Sweden

4. Department of Pharmacy & Pharmacology Antoni van Leeuwenhoek Hospital Netherlands Cancer Institute Amsterdam The Netherlands

5. Department of Clinical Pharmacy University Medical Centre Utrecht (UMCU) Utrecht University Utrecht The Netherlands

6. Department of Hematology University Medical Centre Utrecht (UMCU) Utrecht University Utrecht The Netherlands

7. Stem Cell Transplant and Cellular Therapies, Pediatrics Memorial Sloan Kettering Cancer Centre New York New York USA

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12486

Reference28 articles.

1. Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors

2. Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation

3. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis

4. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis

5. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T-cell therapy and fludarabine: precision dosing imperatives;Blood Advances;2024-02-02

2. Virtual Patient Simulation Using Copula Modeling;Clinical Pharmacology & Therapeutics;2023-11-24

3. Pharmacokinetic–Pharmacodynamic Modeling and Simulation in Clinical Practice and Studies;AAPS Introductions in the Pharmaceutical Sciences;2023

4. Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan;Pharmaceuticals;2021-06-26

5. Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety;Pharmaceutical Research;2021-03-17